Orforglipron

Overview

First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.

Mechanism of action

Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.

Key research findings

• Significant weight loss (up to 12.4% at 72 weeks)
• Robust diabetes control (HbA1c reduction 1.3-1.6%)
• Once-daily oral tablet format
• No refrigeration or food restrictions required
• Reduced cardiovascular risk markers

Research applications

Weight Loss

• Obesity Without Diabetes — ATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
• Obesity With Type 2 Diabetes — ATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
• Cardiometabolic Risk Reduction — Improvements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
• Prediabetes Prevention — 91% achieved near-normal blood sugar levels versus 42% with placebo.

Type 2 Diabetes

• Type 2 Diabetes Management — ACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
• Insulin Resistance Improvement — Significant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.